Synthesis of oligoribonucleotides containing 4-thiouridine using the convertible nucleoside approach and the 1-(2-fluorophenyl)-4-methoxypiperidin-4- yl group by Aviñó, Anna et al.
“Synthesis of oligoribonucleotides containing 4-thiouridine using the convertible nucleoside 
approach and the Fpmp group.” Aviñó, A., Güimil-García, R., Eritja, R. Nucleosides, 
Nucleotides & Nucleic Acids, 23(11), 1767-1777 (2004). 
PMID: 15598077, doi: 10.1081/NCN-200034044 
 
 
SYNTHESIS OF OLIGORIBONUCLEOTIDES CONTAINING 4-THIOURIDINE USING 
THE CONVERTIBLE NUCLEOSIDE APPROACH AND THE 1-(2-FLUOROPHENYL)-
4-METHOXYPIPERIDIN-4-YL GROUP. 
 
Anna Aviñó, Ramon Güimil García& and Ramon Eritja
∗  
 
Instituto de Biología Molecular de Barcelona, C.S.I.C. Jordi Girona 18-26, E-08034 
Barcelona, Spain  
&Present address: febit ag, Käfertaler Strasse 190, D-68167 Mannheim 
 
 
ABSTRACT 
 
Oligoribonucleotides containing 4-thiouridine were prepared using the Fpmp group for 
protection of the 2’-OH. Two uridine derivatives with the 1,2,4-triazolyl and the 2-
nitrophenyl groups at position 4 were used to obtain 4-thiouridine by postsynthetic 
substitution with sodium hydrogen sulfide. Both uridine derivatives allow the preparation of 
the desired oligonucleotides in good yields.   
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INTRODUCTION 
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Photochemical cross-linking can be used to characterize RNA-protein interactions by 
trapping transient complexes, which can be difficult to isolate.1-3 One of the most common 
strategies used in photochemical photochemical cross-linking is to incorporate photoreactive 
nucleotide analogs at defined positions. These photoreactive nucleotides can be incorporated 
into the RNA chains by in vitro transcription and/or RNA ligation.1-3 Recent advances in 
chemical synthesis of RNA have opened up the possibility of obtaining short RNA 
molecules containing some of these photoreactive nucleosides by chemical synthesis. 
Specifically the synthesis of oligoribonucleotides containing the photoreactive nucleosides 
5-bromo-, 5-iodo- and 4-thiouridine has been described.4-8 For the preparation of 5-
thiouridine oligoribonucleotides, the S-cyanoethyl-protected 4-thiouridine phosphoramidite 
derivative4,6,7 has been used. 
Another possibility is to prepare an uridine derivative carrying a leaving group in position 4. 
After the assembly of the desired sequence this derivative can be converted to thiouridine by 
nucleophilic displacement with a thiol. This strategy, known as the convertible nucleoside 
approach9 or the postsynthetic modification approach10, has been used to prepare 
oligoribonucleotides carrying N-alkyl-cytosine derivatives11 and 4-thiouridine5,8. In these 
studies, 2’-OH were protected as a tert-butyldimethylsilyl (TBDMS) ethers. 
We are interested in the preparation of oligoribonucleotides carrying photoreactive 
nucleosides such as 4-thiouridine. In this paper, we describe the preparation and use of two 
uridine derivatives for the synthesis of 4-thiouridine oligoribonucleotides. The 2'-OH of the 
phosphoramidite derivatives is protected by the 1-(2-fluorophenyl)-4-methoxypiperidin-4-yl 
(Fpmp) group12-14. In this way, Fpmp-protected RNA intermediates can be isolated, 
facilitating the characterization of the products.  
 
RESULTS AND DISCUSSION 
 
Preparation of Oligonucleotides Carrying 4-Thiouridine Using the 1,2,4-Triazolyl 
Derivative of Uridine. 
Nucleoside derivatives carrying good leaving groups at specific positions can be used to 
obtain oligonucleotides carrying modified bases4,5,8-11. The 1,2,4-triazolyl group5,15,16 was 
first selected to activate the position 4 of the uracil base in order to obtain 4-thiouridine. To 
study the displacement conditions we prepared the 1,2,4-triazolyl derivative of 2’,3’,5’-tri-
O-acetyluridine. 2’,3’,5’-Tri-O-acetyluridine17 (1, Figure 1) was reacted with a solution of 
phosphoryl tristriazolide5,16  prepared by mixing POCl3, 1,2,4-triazol and triethylamine in 
dry CH3CN. Compound 2 was then treated with a 0.2 M solution of thiolacetic acid in 
CH3CN and with a 0.2 M solution of NaSH in dimethylformamide (DMF). Both gave the 
desired 2’,3’,5’-tri-O-acetyl-4-thiouridine (3, Figure 1) but the reaction with NaSH was 
faster finishing after 3 hr at room temperature. 
 
FIGURE 1 
 
Next, the commercially available uridine phosphoramidite carrying the Fpmp group for the 
protection of the 2’-OH was reacted with the phosphoryl tristriazolide5 solution giving 
compound 4 (Figure 1) in 85% yield after purification on silica gel.  
Phosphoramidite 4 was reacted with thymidine linked to a controlled pore glass (CPG) 
support to obtain after regular phosphite oxidation the dinucleotide sequence A: 5' triUT 3' 
(where triU is 4-(1,2,4-triazol-1-yl)-2-pyrimidon-1-yl-β-D-ribofuranoside). The coupling 
reaction of phosphoramidite 4 proceeded in 95% yield, according to the absorbance of the 
DMT group released after the coupling reaction. The resulting support was then treated with 
a 0.2 M NaSH solution in DMF at room temperature for 3 hours, and, afterwards, with conc. 
NH3 for 1 hr at room temperature to release the dinucleotide from the support and remove 
the cyanoethyl group. Only one peak was observed, which was collected and found to have 
the expected molecular weight. 
Oligoribonucleotide sequences B: 5' triUG 3' and C: 5'CUAGU(triU)CGAU 3' were 
assembled on a DNA synthesizer using Fpmp-protected nucleoside 2-cyanoethyl 
phosphoramidites and solid supports. The resulting supports were treated with a 0.2 M 
NaSH solution in DMF, and with conc. NH3. In these oligonucleotides ammonia treatment 
must be longer than one hour in order to remove the protecting groups of the bases. The 
effect of the ammonia treatment was studied on the dinucleotide B. Overnight treatment at 
50ºC removed the thiol group of 4-thiouridine yielding the dinucleotide carrying cytidine or 
uridine. The side product is more polar than the desired oligonucleotide and it is easily 
separated by HPLC (see Figure 2b). In this way, the side product was isolated and 
characterized by mass spectrometry (MS, electrospray, found1002.4 expected for 
CFpmpGFpmp 1002.8, expected for UFpmpGFpmp 1003.8). The formation of this side product is 
reduced by lowering the temperature (24 hr, at room temperature) or the time of the 
ammonia treatment (4 h, 50ºC, Figure 2a). Using a 4 h treatment at 50ºC decamer C was 
obtained as the major product, and had the expected molecular weight. Dinucleotide 5' 4SUG 
3' was used to initiate the transcription by T7 RNA polymerase. In this way, longer RNA 
transcripts with 4-thiouridine at the 5’-end were obtained and used to study proteins 
involved in RNA splicing, as described previously18. 
 
FIGURE 2 
 
We also found that samples with the (1,2,4-triazolyl) derivative should be processed rapidly. 
After three months, both the phosphoramidite 4 and oligonucleotide supports carrying the 
(1,2,4-triazolyl) derivative had lost the capacity to produce 4-thiouridine. It is believed that 
the (1,2,4-triazolyl) derivative is hydrolyzed by humidity to yield uridine even if the samples 
are maintained frozen. On the other hand, the 1,2,4-triazolyl derivative of thymidine is much 
more stable. The presence of the methyl group in thymidine may prevent hydrolysis by 
steric and electronic effects. For this reason, a new uridine derivative was prepared. 
 
Preparation of Oligonucleotides Carrying 4-Thiouridine Using the 2-Nitrophenyl Derivative 
of Uridine. 
The synthesis of the phosphoramidite derivative of 4-(2-nitrophenyl)uridine is shown in 
Figure 3. 3’,5’-O-Tetraisopropyldisiloxane-1,3-dilyl)-4-O-(2-nitrophenyl)uridine (5) was 
prepared as described19. Compound 5 was reacted with 1-(2-fluorophenyl)-4-methoxy-
1,2,5,6 tetrahydropyridine12 to give the 2’-Fpmp derivative 6 in 62% yield. Removal of the 
silyl group with tetrabutylammonium fluoride produced compound 7 in 86% yield. 2’-Fpmp 
derivative 7 was reacted with dimethoxytrityl chloride and the resulting compound 8 was 
reacted with 2-cyanoethoxy-N,N-diisopropylamino-chlorophosphine to obtain the desired 
phosphoramidite 9 in 91% yield.  
 
FIGURE 3 
 Phosphoramidite 9 was reacted with thymidine linked to a controlled pore glass (CPG) 
support to obtain the dinucleotide sequence A: 5' npUT 3' (being npU: 4-(2-nitrophenyl)-
uridine. The coupling reaction of phosphoramidite 9 proceeded in 94% yield, similar to the 
Fpmp phosphoramidites of the natural nucleosides. The resulting support was then treated 
with a 0.2 M NaSH solution, and with conc. NH3 at room temperature. Only one peak was 
observed, which was collected and found to have the expected molecular weight. 
Oligoribonucleotide sequence E: 5’ UAC(npU)GU 3' was prepared using the appropriate 
Fpmp phosphoramidites. The support was treated with a 0.2 M NaSH solution and the 
resulting support was then treated with conc. ammonia as described above, producing the 
desired thiouridine oligonucleotide in good yields. This phosphoramidite maintained its 
properties for at least two years when frozen. 
 
FIGURE 4 
 
 
CONCLUSION 
We have shown that oligoribonucleotides containing 4-thiouridine can be prepared from two 
different precursors: first, the 4-(1,2,4-triazolyl) derivative which can be obtained from the 
readily available uridine phosphoramidite carrying the Fpmp group at position 2’ but which 
has a limited shelf-life; second, the 4-(2-nitrophenyl) derivative, which requires a longer 
synthetic scheme but, once prepared, presents a longer shelf-life. These derivatives may be 
also used for N-15 labelling and preparation of oligonucleotides carrying N-alkyl-C 
derivatives similarly as described with the 4-chlorophenyl uridine derivative.11 
 
EXPERIMENTAL SECTION 
 
Abbreviations: A260: absorbance at 260 nm, controlled pore glass (CPG), DMF: N,N-
dimethylformamide, DMT: dimethoxytrityl, Fpmp: 1-(2-fluorophenyl)-4-methoxypiperidin-
4-yl, OD: optical density units at 260 nm, THF: tetrahydrofuran, npU: 4-O-(2-
nitrophenyl)uridine, 4SU: 4-thiouridine; triU: 4-(1,2,4-triazol-1-yl)-2-pyrimidon-1-yl-β-D-
ribofuranoside. 
 
General Procedures. Solvents, including those of HPLC grade, were from SDS and E. 
Merck. Reagents were from Aldrich and Fluka and were used without further purification. 
Analytical TLC was run on aluminium sheets coated with silica gel 60 F254 from Merck. 
Silica gel column chromatography was performed with Chromatogel 60 A C.C. (40-60 
microns, 230-400 mesh, SDS). Fpmp-protected phosphoramidites and 1-(2-
fluorophenyl)piperidin-4-one were obtained from Cruachem Ltd (Scotland). 1-(2-
Fluorophenyl)-4-methoxy-1,2,5,6 tetrahydropyridine was prepared from 1-(2-
fluorophenyl)piperidin-4-one as described12. 2´,3’,5’-tri-O-acetyluridine (1) was prepared by 
the reaction of uridine with acetic anhydride in pyridine17. 3’,5’-O-Tetraisopropyldisiloxane-
1,3-dilyl)-4-O-(2-nitrophenyl)uridine (5) was prepared as described with minor 
modifications19. 1H-NMR (250 MHz), 13C-NMR (63 MHz) and 31P-NMR (75 MHz) spectra 
were recorded on a Bruker AM-250. HPLC chromatography was performed on an HPLC 
Waters equipped with an UV detector at 260 nm. 
 
Standard Work-Up. All reactions were carried out in oven-dried glassware, under a nitrogen 
or argon atmosphere, unless specified otherwise. Before use, starting materials were dried 
by evaporation with the dry solvent that will be used for the reaction. Once the reaction was 
completed, solutions were concentrated to dryness and the residues were dissolved in 
CH2Cl2 or CHCl3 and washed with 5% aqueous NaHCO3 and saturated aqueous NaCl. The 
organic phase was dried (Na2SO4) and the solvent was removed. 
 
2’,3’,5’-O-Triacetyl-4-(1,2,4-triazol-1-yl)-2-pyrimidon-1-yl-β-D-ribofuranoside (2). 
To an ice-cooled stirred suspension of 1,2,4-triazole (1,5 g, 21.7 mmol) in dry CH3CN (30 
ml) 0.42 ml (4.2 mmol) of POCl3 were added, followed by 3.27 ml ( 23.4 mmol) of dry 
Et3N. After 30 min a solution of 2´,3’,5’-tri-O-acetyluridine17 (1) (2 mmol) in dry CH3CN 
was added over a period of 15 min and stirred for 2 h. The reaction was stopped by addition 
of 25 ml of a saturated NaHCO3 aqueous solution and, 50 ml of ethyl acetate were added. 
The organic phase was washed with brine, dried over Na2SO4 and concentrated to dryness. 
The resulting product (0.85 g unpurified with Et3N) was used in the next step without further 
purification. TLC (10% MeOH in CH2Cl2) one single fluorescent spot of Rf = 0.7. UV (max, 
MeOH) 243, 302 nm. 
 
2’,3’,5’-Tri-O-acetyl-4-thiouridine (3). 
1) Reaction with thiolacetic acid. Compound 2 (0.24 mmol) was treated with 0.142 ml (2 
mmol) of thiolacetic acid dissolved in 10 ml of CH3CN. After one day of magnetic stirring 
at room temperature conversion to 2’,3’,5’-triacetyl thiouridine was judged to be around 
50% by TLC (10% CH3OH in CH2Cl2, starting material Rf= 0.7 fluorescent, final product 
Rf= 0.8 non fluorescent). After 2 days the reaction was practically finished. The reaction 
mixture was concentrated to dryness and treated using the standard work-up described 
above. The product was purified by column chromatography. Yield: 58% (53 mg, 0.14 
mmol). Physical and spectroscopic data agreed with literature values20. 
2) Reaction with sodium hydrogen sulfide. 2’,3’,5’-O-Triacetyl-4-(1,2,4-triazolyl)uridine 
(0.24 mmol) was treated with 148.2 mg (2 mmol) of sodium hydrogensulfide in 10 ml DMF. 
After 3 hr of magnetic stirring the conversion was judged to be completed by TLC (see 
above). The reaction mixture was concentrated to dryness and treated using the standard 
work-up described above. The product was purified by column chromatography. Yield: 62 
% (60 mg, 0.15 mmol. Physical and spectroscopic data agreed with literature values20. 
 
5'-O-Dimethoxytrityl-2'-O-[1-(2-fluorophenyl)-4-methoxypiperidin-4-yl]-4-(1,2,4-
triazolyl)uridine 3'-O-[2-cyanoethyl-N,N-(diisopropylamino)] phosphoramidite (4).  
The protocol described by Shah et al.5 was used for the preparation of this phosphoramidite. 
To an ice-cooled suspension of 1,2,4-Triazole (1.04 g, 15.5 mmol) in dry CH3CN (20 ml) 
was added 0.3 ml of POCl3 was added, followed by 2.25 ml of dry Et3N. After 30 min a 
solution of the DMT-U(Fpmp) phosphoramidite (188 mg, 0.25 mmol) in dry CH3CN was 
added over a period of 15 min and stirring was continued for 2 hr. After standard work-up, 
the product was purified by column chromatography (ethyl acetate/ CH2Cl2 2:3 + 1% 
triethylamine). Yield 170 mg, 85%. 31P-NMR (CDCl3): 151.3, 150.2 (two diastereoisomers).  
 
TABLE 1 
 3',5'-O-(Tetraisopropyldisiloxane-1,3-diyl)-2'-O-[1-(2-fluorophenyl)-4-methoxypiperidin-4-
yl]-4-O-(2-nitrophenyl)uridine (6).  
3',5'-O-(Tetraisopropyldisiloxane-1,3-diyl)-4-O-(2-nitrophenyl)uridine18 (2.43g, 4 mmol) 
and 1-(2-fluorophenyl)-4-methoxy 1,2,5,6-tetrahydropyridine (4.95 g , 24 mmol) were 
dissolved in dry THF (40 ml). Mesitylenesulfonic acid dihydrate (0.25 g, 1.05 mmol) was 
dried by coevaporation of dry CH3CN (2 x 20 ml) under reduced pressure. The dried 
mesitylenesulfonic acid was dissolved in dry CH3CN (10 ml) and added to the THF solution. 
The reaction mixture was stirred overnight under anhydrous conditions, whereupon TLC 
showed an almost complete reaction. Triethylamine was added and after 5 minutes, THF 
was evaporated and the residue was dissolved in CH2Cl2. The solution was treated with the 
standard work-up described above. The residue was purified on silica gel using a 0-4% 
CH3OH gradient in CH2Cl2.Yield: 2.04 g (2.5 mmol) 62%. Anal. Calcd for 
C39H55FN4O10Si2: C 57.47, H 6.80, N 6.87. Found C 57.05, H 6.67, N 6.61%. MS (FAB+) 
m/z: calculated for C39H55FN4O10Si2, 815; found 814.8 [M+],. 
 
2'-O-[1-(2-Fluorophenyl)-4-methoxypiperidin-4-yl]-4-O-(2-nitrophenyl)uridine (7). 
Compound 6 (2.04g , 2.5 mmol) was dissolved in dry THF (50 ml) and 1.1 M 
tetrabutylammonium fluoride in THF (5.5 ml) was added with stirring. Silica gel TLC in 
ethanol/ CH2Cl2 (5: 95, v/v) showed a complete reaction after 5 minutes with a spot of 
Rf.0.32. The reaction mixture was quenched with 16 ml of pyridine/methanol/water (3:1:1), 
and the solution was poured into stirred Dowex 50Wx4 (200 mesh, pyridinium form) resin 
suspended in 100 ml of pyridine/methanol/water (3:1:1). The mixture was stirred for 20 min, 
the resin filtered off and washed with the same mixture (3 x 50 ml). The combined filtrates 
and washings were evaporated to dryness in vacuo. The residue was purified by column 
chromatography on silica gel eluting with a gradient from 0 to 15% ethanol in CH2Cl2. 
Yield: 1.24 g (2.16 mmol) 86%. Anal. Calcd for C27H30FN4O9: C 56.54, H 5.27, N 9.77. 
Found C 56.28, H 5.01, N 9.54%. MS (FAB+) m/z: calculated for C27H30FN4O9, 573.5 ; 
found 573.9 [M+]. 
 
5'-O-Dimethoxytrityl-2'-O-[1-(2-fluorophenyl)-4-methoxypiperidin-4-yl]-4-O-(2-
nitrophenyl)uridine (8). 
Compound 7 (1.24g , 2.16 mmol) was dried by evaporation of pyridine (3 x 1,5 ml) in 
vacuo. Anhydrous pyridine (30 ml) and 4,4’-dimethoxytrityl chloride (0.9 g 2.65 mmol) 
were added with stirring and exclusion of moisture. Silica gel TLC in triethylamine / ethanol 
/ CH2Cl2 (1:10:89, v/v/v) showed a complete reaction after 1.5 h with a new spot of Rf. 0.65. 
The reaction was quenched by addition of methanol (5 ml) and the solvent was removed in 
vacuo. The residual oil was dissolved in ethyl acetate (50 ml) and the solution was washed 
as described above in the standard work-up. Residual pyridine was removed by evaporation 
of toluene in vacuo. The crude product was purified by column chromatography. The 
column was packed using a 1% triethylamine solution in CH2Cl2 and the product was eluted 
with a 0-10% methanol gradient in CH2Cl2. Compound 8 was obtained as a white foam. 
Yield: 1.69 g (1.93 mmol) 89%. Anal. Calcd for C48H48FN4O11.2/3 CH2Cl2: C 62.76, H 5.34, 
N 6.02. Found C 62.40, H 5.21, N 6.04%. MS (FAB+) m/z: calculated for C48H48FN4O11, 
875.9; found 874.9 [M+], 896.7 [M+Na+]. 
 
5'-O-Dimethoxytrityl-2'-O-[1-(2-fluorophenyl)-4-methoxypiperidin-4-yl]-4-O-(2-
nitrophenyl)uridine 3'-O-[2-cyanoethyl-N,N-(diisopropylamino)] phosphoramidite (9). 
Compound 8 (1g , 1.14 mmol) was dried by evaporation of dry CH3CN (3 x 10 ml) in vacuo. 
The residual foam was dissolved in dry 1,2-dichloroethane (30 ml) containing N,N-
diisopropylethylamine (0.6 ml , 3.42 mmol) and the solution (under argon) was cooled in an 
ice bath. 2-Cyanoethoxy-N,N-diisopropylamino-chlorophosphine (0.4 ml , 1.71 mmol) was 
added drop wise with stirring during approx. 1 min. The mixture was kept 10 min at 0°C and 
was then stirred for 1 h at room temperature. TLC in triethylamine/ CH2Cl2 showed a 
complete reaction with a product spot of Rf. 0.55. Dichloromethane (50 ml) was added and 
the solution was washed as described above in the standard work-up. The product was 
purified by column chromatography on silica gel using CH2Cl2/ n-hexane (5:2) containing 
2% triethylamine as eluant. Yield: 1.12 g (1.04 mmol) 91%. 31P-NMR (Cl3CD) δP: 150.8 
and 149.7 ppm. Anal. Calcd for C57H65FN6O12P: C 63.62, H 6.09, N 7.81. Found C 63.25, H 
6.13, N 7.69%.MS (FAB+) m/z: calculated for C57H65FN6O12P, 1076.1; found 1097.1 
[M+Na+]. 
 Oligonucleotide Synthesis and Purification. 
Sequences A: 5' triUT 3', B: 5' triUG 3', C: 5'CUAGU(triU)CGAU 3', D: 5' npUT 3', and E: 5’ 
UAC(npU)GU 3' were assembled using 35 mg (1 µmol) of the appropriate supports and 
Fpmp-protected nucleoside 2-cyanoethyl phosphoramidites on a DNA synthesizer (Applied 
Biosystems Mod. 394). Standard 1 µmol scale RNA synthesis cycles were used. Coupling 
efficiencies were higher than 96%. The last DMT group was removed before deprotection 
(DMT off) except in sequences C and E, in which it was not removed (DMT on) so as to 
facilitate HPLC purification.  
After the assembly of the sequences, supports were treated with a 0.2 M NaSH solution in 
DMF (2 ml) at room temperature for 3 hours. The supports were washed with DMF and 
CH3CN and dried. The resulting supports were treated with concentrated ammonia at 50 ºC 
for 4 hours. The resulting Fpmp oligonucleotides were purified by reverse-phase HPLC. 
HPLC conditions were as follows: Column : Nucleosil 120C18 (200 x 4 mm), flow rate 1 ml 
/ min, a 30 min linear gradient from 10 to 55% CH3CN over 20 mM aqueous 
triethylammonium acetate. Overall (synthesis and purification) yields were: sequence A (1 
μmol scale): 5 OD, sequence B (4 μmol scale): 41 OD, sequence C (1 μmol scale): 19 OD, 
sequence D (1 μmol scale): 4 OD and D: (1 μmol scale): 11 OD. All oligonucleotides have 
an UV maximum near 320 nm in addition to the maximum near 260 nm. Oligonucleotides 
were analyzed by mass spectrometry (electrospray). 5’ 4SUFpmpT 3’: found 771.4 (M) 
calculated for C31H39FN5O13PS 771.5; 5’ 4SUFpmpGFpmp 3’: found 1019.0 (M) calculated for 
C43H52F2N9O14PS 1019.8; 5' DMT-CFpmpUFpmpAFpmp GFpmpUFpmp4SUFpmp 
CFpmpGFpmpAFpmpUFpmp 3': found 5511.1 (M) calculated for C227H275F10N44O83P9S 5448.1; 5’ 
DMT-UFpmpAFpmpCFpmp4SUFpmpGFpmpUFpmp 3': found 3399.3 (M) calculated for 
C149H173F6N25O49P5S 3398.3. The Fpmp and DMT groups were removed by treatment of the 
samples with 0.5 ml of 10 mM aqueous HCl (pH 2.5-3) at room temperature overnight13,14. 
The samples were neutralized by adding 25 μl of sterile 2M Tris acetate pH 7 followed by 
ethanol precipitation of RNA with 3 volumes of ethanol and 1/10 of volume of sterile 3M 
sodium acetate. Mass spectrometry (MALDI-TOF). 5’ 4SUT 3’: found 586.4 (M+Na-H)- 
calculated for C19H25N4O12PS 564.3; 5’ 4SUG 3’: found 627.5 (M+Na-H)- calculated for 
C19H24N7O12PS 605.3. 
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 FIGURE LEGENDS: 
 
Figure 1: Uridine derivatives 1-4 
 
Figure 2: HPLC purification of dinucleotide 5’ 4SUFpmpGFpmp 3’. Oligonucleotide support 
B: 5' triUG 3' was treated with a 0.2 M NaSH solution in DMF at room temperature for 3 
hours and the resulting supports were treated with concentrated ammonia a) at 50 ºC for 
4 hours and b) at 50 ºC overnight.   
 
Figure 3: Uridine derivatives 5-9 carrying the 2-nitrophenyl group 
 
Figure 4: HPLC purification of oligonucleotide sequence E.  
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